» Articles » PMID: 32002828

Metabolically Healthy Obesity is Associated with Longitudinal Changes in High-density Lipoprotein Cholesterol in Chinese Adults

Overview
Publisher Springer
Date 2020 Feb 1
PMID 32002828
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Whether metabolically healthy obesity (MHO) is associated with longitudinal changes in high-density lipoprotein cholesterol (HDL-C) remains unclear.

Methods: MHO was defined as participants with overweight and obesity (BMI ≥ 24.0 kg/m, n = 2921), free of history of metabolic diseases, and without abnormalities of blood pressure, fasting blood glucose, hemoglobin A1c, lipid profile, carotid artery and liver ultrasonographic findings at baseline. Metabolically healthy normal weight (MHN) was defined as participants with normal weight (BMI < 24.0 kg/m, n = 9578) and without above-mentioned abnormalities. HDL-C, fasting blood glucose, hemoglobin A1c, and blood pressure were assessed annually. Glucose abnormality was considered if either FBG ≥ 5.6 mmol/L or HbA1c ≥ 5.7%; while, high blood pressure (HBP) was considered if either systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg during 5 years of follow-up.

Results: Compared with the MHN group, the adjusted mean difference in HDL-C change rate was - 0.005 mmol/L per year [95% confidence interval (CI) - 0.007, - 0.003] for MHO after adjustment for a series of potential confounders. Furthermore, transiting to abnormality of blood glucose, but not high blood pressure, was associated with lower cumulative average of HDL-C in MHN group, compared with those remained in metabolically healthy status.

Conclusions: MHO and transiting from metabolically healthy to abnormality of blood glucose were associated with HDL-C in Chinese adults.

Level Of Evidence: III, cohort study.

Citing Articles

The Association between Serum Level of Vitamin D and Inflammatory Biomarkers in Hospitalized Adult Patients: A Cross-Sectional Study Based on Real-World Data.

Zhang X, Chen Z, Xiang Y, Zhou Y, Tang M, Cai J Mediators Inflamm. 2024; 2024:8360538.

PMID: 38549715 PMC: 10978080. DOI: 10.1155/2024/8360538.


Metabolism Score for Visceral Fat (METS-VF): A New Predictive Surrogate for CKD Risk.

Feng L, Chen T, Wang X, Xiong C, Chen J, Wu S Diabetes Metab Syndr Obes. 2022; 15:2249-2258.

PMID: 35936056 PMC: 9346409. DOI: 10.2147/DMSO.S370222.


Agmatine and glycolipid metabolism.

Zhang Y, Yuan S, Che T, He J Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(8):889-893.

PMID: 34565735 PMC: 10929974. DOI: 10.11817/j.issn.1672-7347.2021.200351.

References
1.
Seidell J, Halberstadt J . The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015; 66 Suppl 2:7-12. DOI: 10.1159/000375143. View

2.
Rangel-Huerta O, Pastor-Villaescusa B, Gil A . Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. 2019; 15(6):93. PMC: 6565659. DOI: 10.1007/s11306-019-1553-y. View

3.
Fock K, Khoo J . Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol. 2013; 28 Suppl 4:59-63. DOI: 10.1111/jgh.12407. View

4.
Cheng F, Gao X, Mitchell D, Wood C, Rolston D, Still C . Metabolic Health Status and the Obesity Paradox in Older Adults. J Nutr Gerontol Geriatr. 2016; 35(3):161-76. DOI: 10.1080/21551197.2016.1199004. View

5.
Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K . Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008; 168(15):1609-16. DOI: 10.1001/archinte.168.15.1609. View